Health

FDA Meeting on Duchenne Drug Review

Updated 2026-07-29 10:10 UTC 1 source Neutral

An FDA expert committee is reviewing Capricor Therapeutics’ treatment for Duchenne muscular dystrophy, a contentious process.

Coverage timeline — 1 article

STAT News

STAT+: FDA expert committee reviews Capricor Therapeutics’ Duchenne drug

STAT is live-blogging an FDA meeting on Capricor Therapeutics’ treatment for Duchenne muscular dystrophy, which has been the subject of a contentious regulatory review.

2026-07-29 10:00 UTC